Overview
Most metabolic-research compounds in this catalog are incretin-system agonists (GLP-1, GIP, and glucagon-receptor ligands) and related signaling molecules. The published literature studies them for metabolic and body-composition research endpoints. This guide describes how the compound is characterized and what that research covers. It is not usage guidance and makes no claim about outcomes from use.
A long-acting amylin receptor agonist frequently studied in combination with GLP-1 agonists in metabolic research.
Evidence at a glance: Includes human-trial data
The cited record for this compound includes human-trial data. Each claim below still states its study type and population, so the scope of that evidence stays explicit.
Molecular identity
- Molecular formula
- C174H278N44O56
- Molecular weight
- 3748.2 g/mol
- CAS number
- 1415456-99-1
- Amino acids
- 32
- Appearance
- White lyophilized powder
- Purity (HPLC)
- 99%
Researched mechanism
Amylin receptor agonism; investigated for additive metabolic effects when combined with GLP-1 agonism.
Described as a mechanism characterized in the literature, not an effect you should expect from use.
What the published research shows
Studied in combination regimens in early clinical work.
Every citation states its study type and population, so preclinical data is never presented as human-efficacy evidence.
How it compares
| Versus | Attribute | Note |
|---|---|---|
| Semaglutide | Class | Different mechanism (amylin vs GLP-1); often co-studied. |
Reconstitution
Concentration math only: adding bacteriostatic water to the vial gives the resulting mg/mL shown below. This is not usage guidance.
| Vial | Bacteriostatic water | Concentration |
|---|---|---|
| 5 mg | 2 mL | 2.5 mg/mL |
| 10 mg | 2 mL | 5 mg/mL |
Storage & stability
| State | Temperature | Duration |
|---|---|---|
| Lyophilized (unopened) | -20°C | 24 months |
| Reconstituted | 2–8°C | up to 4 weeks |
Common questions
Why is it studied with GLP-1 agonists?+
Published research pairs amylin and incretin mechanisms; see the cited literature above.
